home / stock / phrm:cc / phrm:cc news

PHRM:CC News and Press, Pharmather Holdings Ltd. From 07/18/23

Stock Information
Company Name: Pharmather Holdings Ltd.
Stock Symbol: PHRM:CC
Market: CNQC
Website: pharmather.com
Menu
PHRM:CC PHRM:CC Quote PHRM:CC Short PHRM:CC News PHRM:CC Articles PHRM:CC Message Board
Get PHRM:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
PHRM:CC - PharmaTher Announces Positive Research Results for PharmaPatch(TM) with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

TORONTO, July 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce that it has successfully completed a research study evaluating ...
PHRM:CC - PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX(TM) (racemic ketamine) to the FDA

TORONTO, June 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has filed a Pre-Submission Facility Correspondence in advanc...

PHRM:CC - PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX(TM) (racemic ketamine) in the U.S.

TORONTO, June 20, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has entered into a collaboration agreement with Vitruvias Th...

PHRM:CC - PharmaTher Holdings Provides Corporate Update

Company funded to meet upcoming milestones over the next 24 months Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and international approvals after that Company advancing PharmaPatch™ (microneedle patch) for psychedelics and in...
PHRM:CC - PharmaTher Holdings Submits Fast Track Application to FDA for KETARX(TM) (Ketamine) for the Treatment of Parkinson's Disease

TORONTO, May 02, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration ( ...

PHRM:CC - Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

Purchased MDMA supply from PharmAla Biotech for upcoming IND-enabling studies Finalizing product and clinical development plans for upcoming studies and potential commercial opportunities TORONTO, April 03, 2023 (GLOBE NEWSWIRE) --  Revive Therapeutics Ltd. (“Revive&#x...

PHRM:CC - PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX(TM) (Ketamine) in Parkinson's Disease

TORONTO, March 29, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced an update on the Type C meeting with the U.S. Food and Drug Administration (“FDA&...
PHRM:CC - PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX(TM) (Ketamine) On-Body Pump System

TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in advancing specialty ketamine pharmaceuticals, today submitted its Type B meeting package with the U.S. Food and Drug Administrati...

PHRM:CC - Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

TORONTO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, i...

PHRM:CC - PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX(TM) (Ketamine) for the Treatment of Rett Syndrome

PharmaTher’s 5 th FDA orphan drug designation for KETARX™ (ketamine) Phase 2 clinical study results to support proposed Phase 3 development of KETARX™ (ketamine) to treat Rett Syndrome for FDA approval via the 505(b)(2) regulatory pathway TORONTO, ...
Previous 10 Next 10